CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.

Trial Details

NCT ID
NCT06479356
Phase
PHASE2
Sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Relma-cel
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • ≥18 years old;
  • Sign on the informed consent;
  • Subjects must have histologically confirmed Large B-cell Lymphoma;
  • Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →